Novasite enters small molecule discovery agreement with Aventis
``This agreement with Aventis represents validation of Novasite's novel approach to drug discovery. We are pleased that Aventis, a world-class pharmaceutical company, recognizes the potential of ETDD to enhance small molecule drug discovery,'' commented William Huse, M.D., Ph.D., CEO of Applied Molecular Evolution, Inc.
Alan Binnie, Ph.D., Program Coordinator at Aventis Pharma's Drug Innovation and Approval Combinatorial Technology Center in Tucson, Arizona, stated, ``We are excited about the potential of Novasite's novel approaches to drug discovery. This pilot project aims to confirm this potential, and thus enable us to consider future collaborations.'' Aventis, a world leader in pharmaceuticals, is dedicated to treating and preventing human disease through the discovery, development, manufacture and sale of innovative pharmaceutical products aimed at fulfilling unmet medical needs.
Novasite Pharmaceuticals
Novasite Pharmaceuticals uses directed evolution technology to enhance small molecule drug discovery and optimization. Novasite's proprietary Expanded Target Drug Discovery(TM) (ETDD) technology is designed to enhance high throughput screening (HTS) by screening chemical libraries against thousands of variants of the target's binding site. The expanded recognition properties of the variant target library enable the identification of novel and high potency leads. Bioinformatic analysis of the large amount of data regarding specific ligand-receptor interactions obtained by the ETDD approach serves to guide the lead optimization process. Novasite is a subsidiary of Applied Molecular Evolution, Inc.
Source: Novasite Pharmaceuticals Inc.